News
Eisai is to move all its global manufacturing of anti-epilepsy drug, Fycompa, to the UK – the first time the pharma company has manufactured a drug outside of Japan. Japanese pharmaceutical company, Eisai, has announced that its UK production facility has received its license…
Results of Novartis’ phase 3 clinical trials show a reduction in acute heart failure deaths in both men and women. Novartis has announced that its investigational medicine, RLX030 (serelaxin), reduced the number of deaths in patients with…
Phase 2 clinical trials of lung cancer drug, amuvatinib, have been discontinued by Astex Pharmaceuticals. Astex Pharmaceuticals, Inc. has announced that clinical development of its lung cancer drug…
Bayer’s CEO comments on the growing pressures pharmaceutical companies are facing and his thoughts on how this may affect new drug development in the future. There is a risk that medical innovation will be undermined due to government pressures on pricing, according to…
AZ, GSK and eight other leading biopharma companies unite with the mission to improve clinical trials and bring new medicines to patients faster. Ten leading biopharmaceutical companies have formed a non-profit organisation to accelerate the…
Over 1 million people in the UK suffer from headaches caused by “medication overuse” of painkillers such as paracetamol or aspirin, according to NICE. Around 1 in 50 people in the UK experience headaches caused by the overuse of painkillers, according to the…
Do you work in one of the top 100 US companies for working mums? A list has been compiled based on childcare and flexibility programs and 26 are in the pharma / healthcare industries. The annual Working Mother’s 100 best American companies list has been announced and 26 pharmaceutical and…
China attempts to face its growing healthcare problems by cutting the prices of its cancer, immunology and blood-related drugs by 17%. Cancer, immunology and blood-related drugs in China will have their maximum retail prices cut by approximately…
Threshold Pharma is to move its pancreatic cancer drug into Phase 3, as investors get spooked by its failure to statistically improve overall survival. Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2…
